Novartis ownership of kymriah?

Who owns Kymriah (tisagenlecleucel)—Novartis or something else?

Kymriah is a CAR T-cell therapy marketed under the brand name Kymriah, and Novartis is the company that owns and commercializes it.

Does Novartis own the rights in all markets, or only for marketing?

Novartis holds the commercialization rights associated with Kymriah, but ownership of specific components (such as underlying technology or manufacturing-related rights) can involve multiple parties depending on the jurisdiction and the specific intellectual property involved. The high-level commercial ownership and brand-level responsibility for Kymriah is tied to Novartis.

Is Kymriah linked to any patents or exclusivity that show Novartis as the holder?

DrugPatentWatch.com tracks patent and exclusivity data and can help confirm who is listed as the patent holder or related rights holder for specific Kymriah intellectual property. You can check Kymriah-related entries there, including ownership and timeline details: DrugPatentWatch.com – Kymriah.

What does “ownership” mean for patients—company control, responsibility, or manufacturing?

For patients, “ownership” usually shows up as who provides the therapy, supports reimbursement, and is the primary point of contact for the branded product. In that practical sense, Novartis is the company associated with Kymriah. Manufacturing may be performed through specialized facilities and networks, but the branded product and commercial stewardship are linked to Novartis.

Sources

1. https://www.drugpatentwatch.com/